Skip to main content
Erschienen in: Current HIV/AIDS Reports 5/2020

01.09.2020 | Central Nervous System and Cognition (SS Spudich, Section Editor)

Relapse of Symptomatic Cerebrospinal Fluid HIV Escape

verfasst von: Francesca Ferretti, Valentina De Zan, Simonetta Gerevini, Filippo Turrini, Enzo Boeri, Nicola Gianotti, Hamid Hasson, Adriano Lazzarin, Paola Cinque

Erschienen in: Current HIV/AIDS Reports | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Symptomatic cerebrospinal fluid (CSF) HIV escape defines the presence of neurological disease in combination antiretroviral therapy (cART)-treated persons due to HIV replication in CSF despite systemic suppression or to higher viral replication in CSF than in plasma. The aim was to search for cases of recurrent symptomatic CSF escape and to define their characteristics.

Recent Findings

By review of the literature, we identified symptomatic CSF escape relapses in three patients who had shown clinical remission of a first escape episode following cART optimization. By examination of our cohort of 21 patients with symptomatic CSF escape, we identified five additional patients. In the latter, viral escape relapsed over a median follow-up of 108 months because of low adherence or upon treatment simplification of a previously optimized regimen. cART reoptimization based on resistance profile and potential drug neuropenetration and efficacy led to relapse resolution with no further episodes after a median follow-up of 50 months from relapse.

Summary

The observation that CSF escape may relapse highlights the importance of long-term neuro-suppressive regimens after a first episode and supports the role of the brain as a reservoir for HIV.
Literatur
1.
Zurück zum Zitat • Mastrangelo A, Turrini F, de Zan Valentina CR, Gerevini S, Cinque P. Symptomatic cerebrospinal fluid escape. AIDS. 2019;33(Suppl 2):S159–69. Extensive review of the published cases of symptomatic cerebrospinal fluid escape.CrossRef • Mastrangelo A, Turrini F, de Zan Valentina CR, Gerevini S, Cinque P. Symptomatic cerebrospinal fluid escape. AIDS. 2019;33(Suppl 2):S159–69. Extensive review of the published cases of symptomatic cerebrospinal fluid escape.CrossRef
2.
Zurück zum Zitat • Winston A, Antinori A, Cinque P, Fox HS, Gisslen M, Henrich TJ, et al. Defining cerebrospinal fluid HIV RNA escape: editorial review. AIDS. 2019;33(Suppl 2):S107–11. A proposal of consensus definitions for cerebrospinal fluid escape. • Winston A, Antinori A, Cinque P, Fox HS, Gisslen M, Henrich TJ, et al. Defining cerebrospinal fluid HIV RNA escape: editorial review. AIDS. 2019;33(Suppl 2):S107–11. A proposal of consensus definitions for cerebrospinal fluid escape.
3.
Zurück zum Zitat • Canestri A, Lescure F-X, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010;50:773–8. First case series describing symptomatic cerebrospinal fluid escape.CrossRef • Canestri A, Lescure F-X, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010;50:773–8. First case series describing symptomatic cerebrospinal fluid escape.CrossRef
4.
Zurück zum Zitat Peluso MJ, Ferretti F, Peterson J, Lee E, Fuchs D, Boschini A, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS. 2012;26:1765–74. Peluso MJ, Ferretti F, Peterson J, Lee E, Fuchs D, Boschini A, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS. 2012;26:1765–74.
5.
Zurück zum Zitat Kugathasan R, Collier DA, Haddow LJ, el Bouzidi K, Edwards SG, Cartledge JD, et al. Diffuse white matter signal abnormalities on magnetic resonance imaging are associated with human immunodeficiency virus type 1 viral escape in the central nervous system among patients with neurological symptoms. Clin Infect Dis. 2017;64:1059–65. Kugathasan R, Collier DA, Haddow LJ, el Bouzidi K, Edwards SG, Cartledge JD, et al. Diffuse white matter signal abnormalities on magnetic resonance imaging are associated with human immunodeficiency virus type 1 viral escape in the central nervous system among patients with neurological symptoms. Clin Infect Dis. 2017;64:1059–65.
6.
Zurück zum Zitat Dravid AN, Natrajan K, Kulkarni MM, et al. Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India. Medicine (Baltimore). 2018;97:e9969.CrossRef Dravid AN, Natrajan K, Kulkarni MM, et al. Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India. Medicine (Baltimore). 2018;97:e9969.CrossRef
7.
Zurück zum Zitat Wendel KA, McArthur JC. Acute meningoencephalitis in chronic human immunodeficiency virus (HIV) infection: putative central nervous system escape of HIV replication. Clin Infect Dis. 2003;37:1107–11.CrossRef Wendel KA, McArthur JC. Acute meningoencephalitis in chronic human immunodeficiency virus (HIV) infection: putative central nervous system escape of HIV replication. Clin Infect Dis. 2003;37:1107–11.CrossRef
8.
Zurück zum Zitat Lescure F-X, Moulignier A, Savatovsky J, Amiel C, Carcelain G, Molina JM, et al. CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity. Clin Infect Dis. 2013;57:101–8. Lescure F-X, Moulignier A, Savatovsky J, Amiel C, Carcelain G, Molina JM, et al. CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity. Clin Infect Dis. 2013;57:101–8.
9.
Zurück zum Zitat • Gray F, Lescure FX, Adle-Biassette H, Polivka M, Gallien S, Pialoux G, et al. Encephalitis with infiltration by CD8+ lymphocytes in HIV patients receiving combination antiretroviral treatment. Brain Pathol Zurich Switz. 2013;23:525–33. Thorough pathological description of CD8+ cell encephalitis.CrossRef • Gray F, Lescure FX, Adle-Biassette H, Polivka M, Gallien S, Pialoux G, et al. Encephalitis with infiltration by CD8+ lymphocytes in HIV patients receiving combination antiretroviral treatment. Brain Pathol Zurich Switz. 2013;23:525–33. Thorough pathological description of CD8+ cell encephalitis.CrossRef
10.
Zurück zum Zitat Mukerji SS, Misra V, Lorenz D, Cervantes-Arslanian AM, Lyons J, Chalkias S, et al. Temporal patterns and drug resistance in CSF viral escape among ART-experienced HIV-1 infected adults. JAIDS J Acquir Immune Defic Syndr. 2017;75:246–55. Mukerji SS, Misra V, Lorenz D, Cervantes-Arslanian AM, Lyons J, Chalkias S, et al. Temporal patterns and drug resistance in CSF viral escape among ART-experienced HIV-1 infected adults. JAIDS J Acquir Immune Defic Syndr. 2017;75:246–55.
11.
Zurück zum Zitat Tong CYW, Costelloe S, Hubb J, Mullen J, O'Shea S, Marta M, et al. Deep sequencing of HIV-1 in cerebrospinal fluid. Clin Infect Dis. 2015;61:1022–5. Tong CYW, Costelloe S, Hubb J, Mullen J, O'Shea S, Marta M, et al. Deep sequencing of HIV-1 in cerebrospinal fluid. Clin Infect Dis. 2015;61:1022–5.
12.
Zurück zum Zitat Gutmann C, Cusini A, Günthard HF, Fux C, Hirschel B, Decosterd LA, et al. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS. 2010;24:2347–54. Gutmann C, Cusini A, Günthard HF, Fux C, Hirschel B, Decosterd LA, et al. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS. 2010;24:2347–54.
13.
Zurück zum Zitat Pasquet A, Ajana F, Melliez H, Giurca C, Poissy J, Yazdanpanah Y. Central nervous system HIV replication and HIV-related pachymeningitis in a patient on protease inhibitor monotherapy despite an undetectable plasma viral load. AIDS. 2012;26:1726–8.CrossRef Pasquet A, Ajana F, Melliez H, Giurca C, Poissy J, Yazdanpanah Y. Central nervous system HIV replication and HIV-related pachymeningitis in a patient on protease inhibitor monotherapy despite an undetectable plasma viral load. AIDS. 2012;26:1726–8.CrossRef
14.
Zurück zum Zitat Mangioni D, Muscatello A, Sabbatini F, Soria A, Rossi M, Bisi L, et al. A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: worth the risk? Clin Infect Dis. 2014;59:1655–6. Mangioni D, Muscatello A, Sabbatini F, Soria A, Rossi M, Bisi L, et al. A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: worth the risk? Clin Infect Dis. 2014;59:1655–6.
15.
Zurück zum Zitat Martins J, Santos E, Salgado P, Maia L, Dias D, Marta M, et al. Recurrent cerebrospinal fluid escape in an HIV-1-infected patient receiving antiretroviral therapy. AIDS. 2016;30:1143–4. Martins J, Santos E, Salgado P, Maia L, Dias D, Marta M, et al. Recurrent cerebrospinal fluid escape in an HIV-1-infected patient receiving antiretroviral therapy. AIDS. 2016;30:1143–4.
16.
Zurück zum Zitat Salam S, Mihalova T, Ustianowski A, McKee D, Siripurapu R. Relapsing CD8+ encephalitis-looking for a solution. BMJ Case Rep. 2016; Published online. Salam S, Mihalova T, Ustianowski A, McKee D, Siripurapu R. Relapsing CD8+ encephalitis-looking for a solution. BMJ Case Rep. 2016; Published online.
17.
Zurück zum Zitat Moloney PB, Hutchinson S, Heskin J, Mulcahy F, Langan Y, Conlon NP, et al. Possible N-methyl-D-aspartate receptor antibody-mediated encephalitis in the setting of HIV cerebrospinal fluid escape. J Neurol. 2020;267:1348–52. Moloney PB, Hutchinson S, Heskin J, Mulcahy F, Langan Y, Conlon NP, et al. Possible N-methyl-D-aspartate receptor antibody-mediated encephalitis in the setting of HIV cerebrospinal fluid escape. J Neurol. 2020;267:1348–52.
18.
Zurück zum Zitat Dravid AN, Gawali R, Betha TP, et al. Two treatment strategies for management of neurosymptomatic cerebrospinal fluid HIV escape in Pune, India. Medicine (Baltimore). 2020;99:e20516.CrossRef Dravid AN, Gawali R, Betha TP, et al. Two treatment strategies for management of neurosymptomatic cerebrospinal fluid HIV escape in Pune, India. Medicine (Baltimore). 2020;99:e20516.CrossRef
19.
Zurück zum Zitat Portegies P, Enting RH, de Gans J, et al. Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam. Netherlands AIDS. 1993;7:669–75.PubMed Portegies P, Enting RH, de Gans J, et al. Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam. Netherlands AIDS. 1993;7:669–75.PubMed
20.
Zurück zum Zitat Vago L, Castagna A, Lazzarin A, Trabattoni G, Cinque P, Costanzi G. Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine. J Acquir Immune Defic Syndr. 1993;6:42–5.PubMed Vago L, Castagna A, Lazzarin A, Trabattoni G, Cinque P, Costanzi G. Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine. J Acquir Immune Defic Syndr. 1993;6:42–5.PubMed
21.
Zurück zum Zitat Gisslén M, Norkrans G, Svennerholm B, Hagberg L. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis. 1997;175:434–7.CrossRef Gisslén M, Norkrans G, Svennerholm B, Hagberg L. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis. 1997;175:434–7.CrossRef
22.
Zurück zum Zitat Pierotti C, Nebuloni M, Bestetti A, et al. Presence of nucleotide excision resistance mutations in cerebrospinal fluid is associated with reduced prevalence of HIV-related brain lesions. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). 2004. Pierotti C, Nebuloni M, Bestetti A, et al. Presence of nucleotide excision resistance mutations in cerebrospinal fluid is associated with reduced prevalence of HIV-related brain lesions. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). 2004.
Metadaten
Titel
Relapse of Symptomatic Cerebrospinal Fluid HIV Escape
verfasst von
Francesca Ferretti
Valentina De Zan
Simonetta Gerevini
Filippo Turrini
Enzo Boeri
Nicola Gianotti
Hamid Hasson
Adriano Lazzarin
Paola Cinque
Publikationsdatum
01.09.2020
Verlag
Springer US
Erschienen in
Current HIV/AIDS Reports / Ausgabe 5/2020
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-020-00526-x

Weitere Artikel der Ausgabe 5/2020

Current HIV/AIDS Reports 5/2020 Zur Ausgabe

Implementation Science (E Geng, Section Editor)

Social Network Interventions for HIV Transmission Elimination

Central Nervous System and Cognition (SS Spudich, Section Editor)

Cognitive and Neurologic Rehabilitation Strategies for Central Nervous System HIV Infection

Behavioral-Bio-Medical Interface (RJ DiClemente and JL Brown, Section Editors)

A Cascade of Interventions to Promote Adherence to Antiretroviral Therapy in African Countries

Central Nervous System and Cognition (SS Spudich, Section Editor)

Immunotherapeutics to Treat HIV in the Central Nervous System

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.